The most common form of lung cancer, and comprises 3 major types: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
Most common in older adult smokers and ex-smokers. Small tumours in the lung are often asymptomatic, so the majority of patients have either locally advanced or metastatic disease at diagnosis.
Most common presenting symptoms are cough, chest pain, haemoptysis, dyspnoea, and weight loss.
A suspicious lung mass can be biopsied during bronchoscopy or using CT guidance. Staging studies (i.e., CT, PET, mediastinal sampling) are required to determine extent of local or regional disease and to evaluate for metastases.
Treatment depends on stage of disease, histological subtype, molecular genotype, and patient comorbidities. Surgery, radiotherapy, and chemotherapy are the most common modalities, but molecular-targeted therapy is important for specific genotypes and immunotherapy is becoming increasingly important.
Lung cancer comprises a group of malignant epithelial tumours arising from cells lining the lower respiratory tract. Lung cancer is divided into 2 categories: non-small cell lung cancer (NSCLC) and small cell lung cancer. NSCLC accounts for more than 80% of all lung cancers.  There are 3 main types of NSCLC (adenocarcinoma, squamous cell carcinoma, and large cell carcinoma) and these are grouped into further subtypes.
Consultant Respiratory Physician
Nottingham University Hospitals
Honorary Professor of Medicine
University of Nottingham
Respiratory Medicine Unit
David Evans Research Centre
City Hospital Campus
DRB has received a lecture fee from Pierre-Fabre and educational grants from Boehringer Ingelheim Ltd, Irwin Mitchell, Roche, and Siemans; DRB has received assistance for travel to an international meeting from OncImmune Ltd.
Consultant Medical Oncologist
Department of Medicine
Royal Marsden Hospital
SP has been paid as a consultant to Eli Lilly and has acted as consultant to AstraZeneca, Boehringer Ingelheim, Clovis Oncology, BMS, MSD, Pfizer, Novartis, and Ariad. SP has received research grants from Pierre Fabre, Otsuka, and Boehringer Ingelheim. SP has received assistance for travel from Boehringer Ingelheim, MSD, and Pfizer.
Professor David R. Baldwin and Dr Sanjay Popat would like to gratefully acknowledge Dr Mick Peake, Dr Chris Kelsey, and Dr Lawrence Marks, previous contributors to this monograph. MP has received lecture fees: AstraZeneca Pharmaceuticals, Lilly Oncology Ltd, Pierre-Fabre, GSK Ltd, and Roche Pharmaceuticals Ltd. MP has also received educational grants to attend scientific conferences from Roche Pharmaceuticals Ltd and Boehringer Ingelheim Ltd. CK and LM declare that they have no competing interests.
AN declares that he has no competing interests.
Assistant Attending Surgeon
Memorial Sloan Kettering Cancer Center
JH declares that he has no competing interests.
Consultant Medical Oncologist
University College Hospital
SML declares that he has no competing interests.
Use of this content is subject to our disclaimer